0 reactions
indianmarketgrid About 1,000 women a year with HER2-low metastatic breast cancer are expected to become eligible for the AstraZeneca-Daiichi therapy.
READ FULL ANALYSIS MEMBER ANALYSIS
THE IMG COMMUNITY
Market insights. Fresh perspectives. Your conversation.
indianmarketgrid About 1,000 women a year with HER2-low metastatic breast cancer are expected to become eligible for the AstraZeneca-Daiichi therapy.